Ewe lambs (n = 24-25) were immunized at 3, 7 and 15 weeks of age with recombinant bovine alpha-inhibin (rec inhibin) or with bovine monoclonal antibody purified inhibin (bMPI) obtained by immunochromatography from bovine follicular fluid or with adjuvant alone (control). Antibodies in the plasma of the lambs immunized with the inhibin preparations bound to iodinated 31 kDa bovine inhibin. Binding was minimal after the primary immunization, increased after each booster immunization and remained elevated until at least 45 weeks of age (29% for rec inhibin and 11% for bMPI). Of the group treated with rec inhibin, 10 ovulated as lambs (control 0/22; bMPI 3/21) and onset of overt oestrous activity (as hoggets) was advanced (P < 0.05) by 17 days in lambs immunized with rec inhibin. As hoggets, the ovulation rate was greater (P < 0.01) in the rec inhibin immunized lambs (4.41 +/- 0.67) than in the control animals (1.27 +/- 0.15) but not in the bMPI-treated lambs (1.40 +/- 0.16). After a further immunization at 17 months of age, however, ovulation rate increased (P < 0.01) in the bMPI-immunized group (3.40 +/- 0.47) but was unchanged in the lambs immunized with rec inhibin (2.80 +/- 0.52) and those in the control group (1.15 +/- 0.08). There were no effects of immunization on plasma concentrations of either follicle stimulating hormone (FSH) or luteinizing hormone (LH). The initial smaller response seen with the bMPI may be due to either the presence of compounds other than inhibin in such preparations or the small absolute amount of inhibin injected.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source
http://dx.doi.org/10.1071/rd9930173DOI Listing

Publication Analysis

Top Keywords

rec inhibin
24
inhibin
12
ovulation rate
12
lambs immunized
12
lambs
8
ewe lambs
8
recombinant bovine
8
weeks age
8
inhibin preparations
8
immunized rec
8

Similar Publications

Background: The increasing number of patients with ovarian insufficiency due to autoimmune disorders, genetic predisposition, or iatrogenic effects of treatment such as cancer therapies necessitates an urgent measure to find a safe and transplantable alternative ovary. A bioengineered ovary is one of the strategies on which the researchers have recently been working. An engineered ovary should be able to mimic the natural ovary aspects.

View Article and Find Full Text PDF

Cancer Treatment and Bone Health.

Calcif Tissue Int

February 2018

Department of Oncology and Metabolism, Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK.

Considerable advances in oncology over recent decades have led to improved survival, while raising concerns about long-term consequences of anticancer treatments. In patients with breast or prostate malignancies, bone health is a major issue due to the high risk of bone metastases and the frequent prolonged use of hormone therapies that alter physiological bone turnover, leading to increased fracture risk. Thus, the onset of cancer treatment-induced bone loss (CTIBL) should be considered by clinicians and recent guidelines should be routinely applied to these patients.

View Article and Find Full Text PDF

Review of seven cases of granulosa cell tumour of the equine ovary.

Vet Rec

September 2011

Equine Reproductive Services, Messenger Farm, Ryton, Malton, North Yorkshire YO17 6RY, UK.

This paper reviews the equine granulosa cell tumour (GCT) and describes the clinicopathological features, treatment and outcome in seven cases of GCT in mares. Mares were presented with unilateral ovarian enlargement during the 2007 to 2010 breeding seasons. The mean (sd) age of the mares was 11.

View Article and Find Full Text PDF

Recombinant FSH and pregnancy-associated plasma protein.

Eur J Obstet Gynecol Reprod Biol

August 2003

Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong Kangnam-Ku, Seoul 135-710, South Korea.

Objectives: To evaluate the effect of rec-FSH on the ovarian follicular environment in controlled ovarian hyperstimulation (COH) cycle, we compared the expression of the markers that have been reported to reflect the follicle health.

Study Design: A total of 31 women (<35 years) with normal ovarian function were allocated to three different COH protocols (urinary FSH (u-FSH)+hMG, rec-FSH only, or u-FSH only). E2, P4, leptin and IGF-I levels in serum or follicular fluid (FF) were measured with radioimmunoassay; cyclin D2, EGF receptor (EGF-R), and inhibin-alpha mRNA levels in luteinized granulosa cells were measured with RT-PCR; and IGFBP-4 and PAPP-A levels in FF were measured with Western blot analysis.

View Article and Find Full Text PDF

Sertoli cell functional reserve was assessed in normozoospermic men and oligozoospermic patients and its prognostic potential was evaluated for patient selection and treatment. For the first objective, three groups of normo-follicle-stimulating hormone (FSH)/normozoospermic fertile men (n:12), normo-FSH/oligozoospermic (n:21) and hyper-FSH/oligozoospermic subfertile men participated in the study whereas for the second objective 24 normo-FSH oligozoospermic patients volunteered for a pilot therapeutic trial. For the first part, high purity (hp) FSH (225 i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!